JP2010507075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010507075A5 JP2010507075A5 JP2009532611A JP2009532611A JP2010507075A5 JP 2010507075 A5 JP2010507075 A5 JP 2010507075A5 JP 2009532611 A JP2009532611 A JP 2009532611A JP 2009532611 A JP2009532611 A JP 2009532611A JP 2010507075 A5 JP2010507075 A5 JP 2010507075A5
- Authority
- JP
- Japan
- Prior art keywords
- age
- biomarkers
- level
- metabolic
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002503 metabolic effect Effects 0.000 claims description 304
- 239000000090 biomarker Substances 0.000 claims description 283
- 150000001875 compounds Chemical class 0.000 claims description 144
- 238000000034 method Methods 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 72
- 239000002207 metabolite Substances 0.000 claims description 64
- 239000000523 sample Substances 0.000 claims description 60
- 239000012472 biological sample Substances 0.000 claims description 56
- 238000011282 treatment Methods 0.000 claims description 26
- 230000008859 change Effects 0.000 claims description 25
- 235000005911 diet Nutrition 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 230000037213 diet Effects 0.000 claims description 11
- 238000012216 screening Methods 0.000 claims description 8
- 238000012360 testing method Methods 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 230000035764 nutrition Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 239000002676 xenobiotic agent Substances 0.000 description 46
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 36
- 201000010099 disease Diseases 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 230000002034 xenobiotic effect Effects 0.000 description 30
- 230000032683 aging Effects 0.000 description 25
- 230000007423 decrease Effects 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 238000002705 metabolomic analysis Methods 0.000 description 20
- 239000005711 Benzoic acid Substances 0.000 description 17
- 235000010233 benzoic acid Nutrition 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 16
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 16
- 230000001431 metabolomic effect Effects 0.000 description 16
- 150000003384 small molecules Chemical class 0.000 description 14
- 230000008238 biochemical pathway Effects 0.000 description 12
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 11
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 11
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 11
- 238000010586 diagram Methods 0.000 description 11
- 229960003104 ornithine Drugs 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 10
- SECPZKHBENQXJG-FPLPWBNLSA-N palmitoleic acid Chemical compound CCCCCC\C=C/CCCCCCCC(O)=O SECPZKHBENQXJG-FPLPWBNLSA-N 0.000 description 10
- 210000002381 plasma Anatomy 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 9
- 238000012544 monitoring process Methods 0.000 description 9
- 230000037361 pathway Effects 0.000 description 9
- 235000002906 tartaric acid Nutrition 0.000 description 9
- 239000011975 tartaric acid Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 8
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 8
- 229960001948 caffeine Drugs 0.000 description 8
- 239000003596 drug target Substances 0.000 description 8
- 238000004817 gas chromatography Methods 0.000 description 8
- 238000004811 liquid chromatography Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000000611 regression analysis Methods 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 235000021319 Palmitoleic acid Nutrition 0.000 description 5
- SECPZKHBENQXJG-UHFFFAOYSA-N cis-palmitoleic acid Natural products CCCCCCC=CCCCCCCCC(O)=O SECPZKHBENQXJG-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- OWYWGLHRNBIFJP-UHFFFAOYSA-N Ipazine Chemical compound CCN(CC)C1=NC(Cl)=NC(NC(C)C)=N1 OWYWGLHRNBIFJP-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- -1 for example Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- RZYHXKLKJRGJGP-UHFFFAOYSA-N 2,2,2-trifluoro-n,n-bis(trimethylsilyl)acetamide Chemical compound C[Si](C)(C)N([Si](C)(C)C)C(=O)C(F)(F)F RZYHXKLKJRGJGP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 101710202061 N-acetyltransferase Proteins 0.000 description 2
- YNYAYWLBAHXHLL-UHFFFAOYSA-N Normetanephrine Chemical compound COC1=CC(C(O)CN)=CC=C1O YNYAYWLBAHXHLL-UHFFFAOYSA-N 0.000 description 2
- YNYAYWLBAHXHLL-MRVPVSSYSA-N Normetanephrine Natural products COC1=CC([C@H](O)CN)=CC=C1O YNYAYWLBAHXHLL-MRVPVSSYSA-N 0.000 description 2
- 238000001790 Welch's t-test Methods 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000021133 dietary differences Nutrition 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000002431 foraging effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- NFBQIWJDUKFHJP-SQOUGZDYSA-N (2r,3s,4r,5r)-3,4,5,6-tetrahydroxy-2-phosphonooxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)OP(O)(O)=O NFBQIWJDUKFHJP-SQOUGZDYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 1
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- ZYOPDNLIHHFGEC-FNORWQNLSA-N Trans-2, 3, 4-Trimethoxycinnamate Chemical compound COC1=CC=C(\C=C\C(O)=O)C(OC)=C1OC ZYOPDNLIHHFGEC-FNORWQNLSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 101150055214 cyp1a1 gene Proteins 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013075 data extraction Methods 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 235000021483 diet soft drink Nutrition 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- 208000022602 disease susceptibility Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000012155 injection solvent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000004108 pentose phosphate pathway Effects 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000007637 random forest analysis Methods 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85146806P | 2006-10-13 | 2006-10-13 | |
| US60/851,468 | 2006-10-13 | ||
| PCT/US2007/081268 WO2008063783A2 (en) | 2006-10-13 | 2007-10-12 | Biomarkers related to metabolic age and methods using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010507075A JP2010507075A (ja) | 2010-03-04 |
| JP2010507075A5 true JP2010507075A5 (enExample) | 2011-01-27 |
| JP5363984B2 JP5363984B2 (ja) | 2013-12-11 |
Family
ID=39430420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009532611A Active JP5363984B2 (ja) | 2006-10-13 | 2007-10-12 | 代謝年齢に関するバイオマーカー及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US7781160B2 (enExample) |
| EP (3) | EP2428587A3 (enExample) |
| JP (1) | JP5363984B2 (enExample) |
| AT (1) | ATE536425T1 (enExample) |
| CA (1) | CA2666339A1 (enExample) |
| WO (1) | WO2008063783A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009153131A1 (en) * | 2008-05-28 | 2009-12-23 | Basf Se | Means and methods for assessing liver enzyme induction |
| CN102105792A (zh) | 2008-05-28 | 2011-06-22 | 巴斯夫欧洲公司 | 评估肝毒性的工具和方法 |
| KR101068996B1 (ko) | 2008-09-18 | 2011-09-30 | 한국표준과학연구원 | 안정동위원소의 질량비를 이용한 동물의 월령 측정 방법 |
| BRPI1007483B1 (pt) * | 2009-01-28 | 2021-11-30 | Bio Preventive Medicine Corporation | Método de diagnóstico de nefropatia in vitro, método in vitro para o monitoramento de progresso de nefropatia, método in vitro para o monitoramento da eficácia de um tratamento de nefropatia, método in vitro de avaliação de toxicidade renal de um agente e kit para diagnóstico de nefropatia |
| EP2642294A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | Phenylacetylglutamine as biomarker for healthy ageing |
| EP2642293A1 (en) | 2012-03-22 | 2013-09-25 | Nestec S.A. | 9-oxo-octadecadienoic acid (9-oxo-HODE)as as biomarker for healthy ageing |
| EP2642295A1 (en) | 2012-03-22 | 2013-09-25 | Nestec S.A. | 1-O-alkyl-2-acylglycerophosphocholine (PC-O) 40:1 as biomarker for healthy ageing |
| EP2642296A1 (en) * | 2012-03-22 | 2013-09-25 | Nestec S.A. | p-Cresol sulphate as biomarker for healthy ageing |
| CL2012001566A1 (es) * | 2012-06-11 | 2013-08-09 | Univ De Santiago De Chile Univ Tecnica Federico Santa Maria | Metodo analitico para verificar la edad de la carne de animales utilizando perfiles volatiles que comprende introducir una fibra de microextraccion en fase solida en un vial que contiene la carne picada que ha sido calentada, luego desorber en el puerto de inyeccion de un cromatografo de gases, separar los gases y determinar sus concentraciones. |
| US20160196766A1 (en) * | 2013-02-20 | 2016-07-07 | Chistopher Brian Lundin | Weight management method |
| WO2015048665A2 (en) * | 2013-09-27 | 2015-04-02 | The Regents Of The University Of California | Method to estimate the age of tissues and cell types based on epigenetic markers |
| JP2017520553A (ja) | 2014-06-30 | 2017-07-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 加齢関連症状及び疾患を治療するためのケト酪酸化合物ならびに組成物 |
| US9737761B1 (en) * | 2014-10-29 | 2017-08-22 | REVVO, Inc. | System and method for fitness testing, tracking and training |
| WO2016124574A1 (en) * | 2015-02-03 | 2016-08-11 | Pharnext | Diagnostic tools for alzheimer's disease |
| US10823699B2 (en) | 2016-07-29 | 2020-11-03 | Vital Biosciences, Inc. | Gel electrophoresis diagnostic kit and methods of using the same |
| CA3048210A1 (en) | 2016-12-23 | 2018-06-28 | Vital Biosciences, Inc. | Electrophoresis diagnostic methods and kits |
| WO2018144911A1 (en) | 2017-02-02 | 2018-08-09 | Golo Llc | Formulations for weight loss and methods of use |
| CN108956790A (zh) * | 2017-05-18 | 2018-12-07 | 中国人民解放军第二军医大学第二附属医院 | 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用 |
| US12080432B1 (en) | 2017-06-01 | 2024-09-03 | The Regents Of The University Of Colorado | Plasma metabolome as a predictor of biological aging |
| CN107273699A (zh) * | 2017-07-07 | 2017-10-20 | 成都脉安科健生物科技有限公司 | 营养指导方案获取方法、装置及电子设备 |
| US11484273B2 (en) * | 2018-03-06 | 2022-11-01 | International Business Machines Corporation | Determining functional age indices based upon sensor data |
| JP7437767B2 (ja) * | 2018-04-24 | 2024-02-26 | 学校法人沖縄科学技術大学院大学学園 | ヒトの老化バイオマーカーとしての、唾液及び尿の代謝物の使用 |
| CN108663448B (zh) * | 2018-05-14 | 2021-07-13 | 中国医学科学院医药生物技术研究所 | 一种复方氨基酸注射液中有关物质的检测方法 |
| WO2020252206A1 (en) * | 2019-06-12 | 2020-12-17 | Huntington Medical Research Institutes | Methods for evaluation and treatment of alzheimer's disease and applications thereof |
| CN110658286B (zh) * | 2019-11-19 | 2022-07-08 | 浙江树人学院（浙江树人大学） | 利用rp-hplc法同时快速检测苯乳酸和4-羟基苯乳酸含量的方法 |
| CN113125589B (zh) * | 2021-03-17 | 2022-01-04 | 广东省农业科学院农业质量标准与监测技术研究所 | 一种代谢组学分析技术鉴定鸭屎香单丛茶的应用 |
| WO2022259950A1 (ja) * | 2021-06-10 | 2022-12-15 | 国立大学法人千葉大学 | 老化の評価方法 |
| CN116798518B (zh) * | 2023-06-05 | 2024-03-08 | 中南大学湘雅医院 | 构建代谢物衰老分数及代谢衰老速率的方法及其应用 |
| CN120280160B (zh) * | 2025-06-10 | 2025-09-19 | 上海交通大学医学院附属仁济医院 | 代谢衰老的识别模型构建系统、存储介质及试剂盒 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096787A (en) * | 1990-08-03 | 1992-03-17 | Globe-Union Inc. | Hydrostatic pump with static resistance for a mobile vehicle battery |
| JP3350189B2 (ja) * | 1993-04-30 | 2002-11-25 | 本田技研工業株式会社 | 電気自動車用バッテリボックス装置 |
| JPH11301077A (ja) | 1998-04-23 | 1999-11-02 | Olympus Optical Co Ltd | ドットコード評価装置及びドットコード評価方法 |
| JPH11301078A (ja) | 1998-04-27 | 1999-11-02 | Ricoh Co Ltd | 複合装置 |
| JPH11301079A (ja) | 1998-04-27 | 1999-11-02 | Canon Inc | 印刷方法、印刷システムおよび記録媒体 |
| CA2381777C (en) * | 1999-08-12 | 2011-10-04 | Wisconsin Alumni Research Foundation | Identification of genetic markers of biological age and metabolism |
| US7329489B2 (en) | 2000-04-14 | 2008-02-12 | Matabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| WO2001078652A2 (en) | 2000-04-14 | 2001-10-25 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| JP3792547B2 (ja) * | 2001-07-19 | 2006-07-05 | 株式会社タニタ | 生体測定装置 |
| EP1451345A4 (en) * | 2001-08-15 | 2006-03-01 | Elixir Pharmaceuticals Inc | MARKERS ASSOCIATED WITH AGE |
| WO2003107270A2 (en) * | 2002-06-14 | 2003-12-24 | Pfizer Limited | Metabolic phenotyping |
| WO2004085996A2 (en) | 2003-03-20 | 2004-10-07 | Albert Einstein College Of Medicine Of Yeshiva University | Biomarkers for longevity and disease and uses thereof |
| AU2004251654A1 (en) * | 2003-06-02 | 2005-01-06 | Icoria, Inc. | Use of genes differentially expressed during aging of liver for treatment and diagnosis |
| JP4255321B2 (ja) | 2003-06-25 | 2009-04-15 | 本田技研工業株式会社 | アシスト搬送方法及びその装置 |
| JP4384896B2 (ja) * | 2003-11-14 | 2009-12-16 | フィールファイン株式会社 | 年齢アセスメントシステム及びプログラム |
| JP2006134676A (ja) | 2004-11-05 | 2006-05-25 | Fuji Electric Fa Components & Systems Co Ltd | 加熱温度制御装置 |
| JP2006134678A (ja) | 2004-11-05 | 2006-05-25 | Toyota Central Res & Dev Lab Inc | 固体高分子型燃料電池及び燃料電池システム |
| JP2006134677A (ja) | 2004-11-05 | 2006-05-25 | Fuji Electric Holdings Co Ltd | 固体高分子型燃料電池用セパレータ及びその製造方法 |
-
2007
- 2007-10-12 EP EP11181263A patent/EP2428587A3/en not_active Withdrawn
- 2007-10-12 CA CA002666339A patent/CA2666339A1/en not_active Abandoned
- 2007-10-12 JP JP2009532611A patent/JP5363984B2/ja active Active
- 2007-10-12 EP EP07868439A patent/EP2089539B1/en active Active
- 2007-10-12 US US11/871,752 patent/US7781160B2/en active Active
- 2007-10-12 WO PCT/US2007/081268 patent/WO2008063783A2/en not_active Ceased
- 2007-10-12 AT AT07868439T patent/ATE536425T1/de active
- 2007-10-12 EP EP14157698.3A patent/EP2813580A1/en not_active Withdrawn
-
2010
- 2010-07-13 US US12/835,307 patent/US20100279337A1/en not_active Abandoned
-
2015
- 2015-11-23 US US14/948,457 patent/US20160116461A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5363984B2 (ja) | 代謝年齢に関するバイオマーカー及びその使用方法 | |
| JP2010507075A5 (enExample) | ||
| Herken et al. | Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: impact of antidepressant treatment | |
| Combs Jr et al. | Determinants of selenium status in healthy adults | |
| EP2227689B1 (en) | Biomarkers for fatty liver disease and methods using the same | |
| Hasselholt et al. | Distribution of vitamin C is tissue specific with early saturation of the brain and adrenal glands following differential oral dose regimens in guinea pigs | |
| BRPI0815095B1 (pt) | Método de classificação de um indivíduo de acordo com a tolerância à glicose predita em tolerância à glicose normal (ngt), tolerância à glicose de jejum prejudicada (ifg), ou tolerância à glicose prejudicada (igt), para diabetes tipo 2, método de determinação da suscetibilidade de um indivíduo a diabetes tipo 2 e método de monitoramento da progressão ou regressão do pré- diabetes em um indivíduo | |
| Loft et al. | Association between 8-oxo-7, 8-dihydroguanine excretion and risk of lung cancer in a prospective study | |
| Lustgarten et al. | Identification of serum analytes and metabolites associated with aerobic capacity | |
| Kunutsor et al. | Serum magnesium and risk of new onset heart failure in men: the Kuopio Ischemic Heart Disease Study | |
| Morris et al. | Modulation of the lipidomic profile due to a lipid challenge and fitness level: a postprandial study | |
| CN105026935B (zh) | 异戊酰甘氨酸作为增重和肥胖倾向的生物标志物 | |
| He et al. | A cross–sectional survey of preschool children: Exploring heavy metal exposure, neurotransmitters, and neurobehavioural relationships and mediation effects | |
| CN108027354B (zh) | 冠心病的生物标志物 | |
| Liu et al. | Associations of plasma carnitine, lysine, trimethyllysine and glycine with incident ischemic stroke: findings from a nested case-control study | |
| Zhang et al. | Arsenic exposure and oxidative damage to lipid, DNA, and protein among general Chinese adults: a repeated-measures cross-sectional and longitudinal study | |
| Castells-Nobau et al. | Microviridae bacteriophages influence behavioural hallmarks of food addiction via tryptophan and tyrosine signalling pathways | |
| Humann-Ziehank et al. | Selenium speciation in paired serum and cerebrospinal fluid samples of sheep | |
| Zhao et al. | L-shaped association between dietary coenzyme Q10 intake and high-sensitivity C-reactive protein in Chinese adults: A national cross-sectional study | |
| Moore et al. | Targeted metabolomics with Ultraperformance liquid chromatography–mass spectrometry (UPLC-MS) highlights metabolic differences in healthy and atopic Staffordshire bull terriers fed two different diets, a pilot study | |
| Jian et al. | Identification of pyruvic and maleic acid as potential markers for disease activity and prognosis in chronic urticaria | |
| Taylor et al. | The metabolome as a diagnostic for maximal aerobic capacity during exercise in type 1 diabetes | |
| Al Rashid et al. | Association of the serum metabolomic profile by nuclear magnetic resonance spectroscopy with sperm parameters: a cross-sectional study of 325 men | |
| Barbosa et al. | Fructose supplementation shifts rat brain metabolism in experimental migraine | |
| Kulkarani et al. | Hypomagnesemia in alcohol dependent population from the lower socio-economic background who were consuming illicit liquor and attending the de-addiction center |